deferoxamine has been researched along with Heart Diseases in 51 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation." | 8.83 | Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006) |
| "Ga-67-DFO-DAS-fibrinogen (Ga-fbg) scintigraphy, a new radiopharmaceutical method, was performed for detecting intraventricular thrombi following acute myocardial infarction in five patients." | 7.67 | [Detection of left ventricular thrombi after acute myocardial infarction using Ga-67-DFO-DAS-fibrinogen]. ( Akioka, K; Hirota, K; Itagane, H; Ochi, H; Oku, H; Takeda, T; Takeuchi, K; Teragaki, M; Yasuda, M, 1988) |
| "We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years." | 7.67 | Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. ( Colan, S; Freedman, MH; Nathan, DG; Olivieri, N; Propper, R; Rose, V; Sallan, D; Wolfe, L, 1985) |
| "For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation." | 4.83 | Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006) |
| "Combination chelation therapy with desferrioxamine and deferiprone has recently been suggested as a more effective tissue iron-chelating treatment for transfusion-dependent beta-thalassemia patients, although a standard dosage protocol has not yet been established." | 3.74 | Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine. ( Aessopos, A; Deftereos, S; Farmakis, D; Kati, M; Polonifi, E; Tsironi, M, 2007) |
| "In patients with thalassemia major (TM) who are non-compliant with long-term deferoxamine (DFO) chelation, survival is limited mainly because of cardiac complications of transfusional siderosis." | 3.72 | Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. ( Berant, M; Hershko, C; Miskin, H; Tamary, H; Yaniv, I, 2003) |
| "Strict lifelong adherence to the standard transfusion and deferoxamine therapy reduces considerably the occurrence of heart failure, LV dysfunction and pericarditis, prevents early heart failure and pulmonary hypertension, but does not eliminate completely cardiac disease in patients with thalassemia major." | 3.72 | Cardiac status in well-treated patients with thalassemia major. ( Aessopos, A; Diamanti-Kandaraki, E; Farmakis, D; Fragodimitri, C; Hatziliami, A; Joussef, J; Karabatsos, F; Karagiorga, M; Meletis, J; Mitilineou, E, 2004) |
| "Ga-67-DFO-DAS-fibrinogen (Ga-fbg) scintigraphy, a new radiopharmaceutical method, was performed for detecting intraventricular thrombi following acute myocardial infarction in five patients." | 3.67 | [Detection of left ventricular thrombi after acute myocardial infarction using Ga-67-DFO-DAS-fibrinogen]. ( Akioka, K; Hirota, K; Itagane, H; Ochi, H; Oku, H; Takeda, T; Takeuchi, K; Teragaki, M; Yasuda, M, 1988) |
| "Sixteen patients (age range, 3 to 17 years) with transfusion-dependent beta-thalassemia major were studied prospectively, beginning at the onset of chelation therapy with deferoxamine (desferrioxamine)." | 3.67 | A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study. ( Gonzalez-Crussi, F; Honig, GR; Ingrisano, C; Lloyd-Still, JD; Maurer, HS, 1988) |
| "We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years." | 3.67 | Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. ( Colan, S; Freedman, MH; Nathan, DG; Olivieri, N; Propper, R; Rose, V; Sallan, D; Wolfe, L, 1985) |
| "Deferiprone, because of its lower molecular weight, might cross into heart mitochondria more efficiently, improving their activity and, thereby, myocardial cell function." | 1.39 | Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major. ( Barone, R; Calvaruso, G; Campisi, S; Capra, M; Caruso, V; Casale, M; Ciancio, A; Cianciulli, P; Cuccia, L; D'Ascola, G; Filosa, A; Gagliardotto, F; Gerardi, C; Maggio, A; Pitrolo, L; Prossomariti, L; Rigano, P; Rizzo, M; Vitrano, A, 2013) |
| "The risk of cardiac death during 1990-1999 and 2000-2008 was compared." | 1.36 | Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. ( Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K, 2010) |
| "Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients." | 1.33 | Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. ( Borgna-Pignatti, C; Cappellini, MD; Cnaan, A; De Stefano, P; Del Vecchio, GC; Forni, GL; Gamberini, MR; Ghilardi, R; Piga, A; Romeo, MA; Zhao, H, 2006) |
| "Deferiprone is an iron chelator that has the potential to be more effective than deferoxamine in removing intracellular iron from the heart." | 1.32 | Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. ( Fogliacco, E; Gaglioti, C; Piga, A; Tricta, F, 2003) |
| "Treatment of patients with beta-thalassemia major has improved dramatically during the past 40 years; however, the current clinical status of these patients remains poorly characterized." | 1.32 | Complications of beta-thalassemia major in North America. ( Cohen, AR; Cunningham, MJ; Macklin, EA; Neufeld, EJ, 2004) |
| " DFO at a dosing level equivalent to 10-fold of that of DXR was useful to obtain protective effects." | 1.31 | The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. ( Al-Rikabi, AC; Najjar, TA; Saad, SY, 2001) |
| "To describe the burden of thalassemia major and its treatment, in terms of prevalence of iron-overload-related complications, direct and indirect costs, and the patient's physical and social well-being." | 1.31 | Impact of thalassemia major on patients and their families. ( Arana, A; Caro, JJ; Eleftheriou, A; Green, TC; Huybrechts, K; Wait, S; Ward, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (37.25) | 18.7374 |
| 1990's | 5 (9.80) | 18.2507 |
| 2000's | 19 (37.25) | 29.6817 |
| 2010's | 8 (15.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Filosa, A | 1 |
| Vitrano, A | 1 |
| Rigano, P | 1 |
| Calvaruso, G | 1 |
| Barone, R | 1 |
| Capra, M | 1 |
| Cuccia, L | 1 |
| Gagliardotto, F | 1 |
| Pitrolo, L | 1 |
| Prossomariti, L | 1 |
| Casale, M | 1 |
| Caruso, V | 1 |
| Gerardi, C | 1 |
| Campisi, S | 1 |
| Cianciulli, P | 1 |
| Rizzo, M | 1 |
| D'Ascola, G | 1 |
| Ciancio, A | 1 |
| Maggio, A | 1 |
| Badat, M | 1 |
| Kaya, B | 1 |
| Telfer, P | 1 |
| Luckie, M | 1 |
| Irwin, B | 1 |
| Nair, S | 1 |
| Greenwood, J | 1 |
| Khattar, R | 1 |
| Ladis, V | 2 |
| Chouliaras, G | 1 |
| Berdoukas, V | 1 |
| Moraitis, P | 1 |
| Zannikos, K | 1 |
| Berdoussi, E | 1 |
| Kattamis, C | 1 |
| Ha, SY | 1 |
| Mok, AS | 1 |
| Chu, WC | 1 |
| Rasalkar, DD | 1 |
| Cheuk, DK | 1 |
| Chiang, AK | 1 |
| Ho, MH | 1 |
| Chan, GC | 1 |
| Mokhtar, GM | 1 |
| Tantawy, AA | 1 |
| Adly, AA | 1 |
| Ismail, EA | 1 |
| Gaur, A | 1 |
| Al-Shabanah, OA | 1 |
| Aleisa, AM | 1 |
| Hafez, MM | 1 |
| Al-Rejaie, SS | 1 |
| Al-Yahya, AA | 1 |
| Bakheet, SA | 1 |
| Al-Harbi, MM | 1 |
| Sayed-Ahmed, MM | 1 |
| Noori, NM | 1 |
| Keshavarz, K | 1 |
| Shahriar, M | 1 |
| Davis, BA | 1 |
| Porter, JB | 1 |
| Jensen, PD | 1 |
| Jensen, FT | 1 |
| Christensen, T | 1 |
| Eiskjaer, H | 1 |
| Baandrup, U | 1 |
| Nielsen, JL | 1 |
| West, M | 1 |
| Malik, GA | 1 |
| Pollock, JC | 1 |
| Westwood, M | 1 |
| Anderson, LJ | 1 |
| Pennell, DJ | 1 |
| Piga, A | 3 |
| Gaglioti, C | 1 |
| Fogliacco, E | 1 |
| Tricta, F | 1 |
| Miskin, H | 1 |
| Yaniv, I | 1 |
| Berant, M | 1 |
| Hershko, C | 2 |
| Tamary, H | 1 |
| Kubota, N | 1 |
| Miyazawa, K | 1 |
| Shoji, N | 1 |
| Sumi, M | 1 |
| Nakajima, A | 1 |
| Kimura, Y | 1 |
| Oshiro, H | 1 |
| Ebihara, Y | 1 |
| Ohyashiki, K | 1 |
| Cunningham, MJ | 1 |
| Macklin, EA | 1 |
| Neufeld, EJ | 2 |
| Cohen, AR | 3 |
| Aessopos, A | 3 |
| Farmakis, D | 2 |
| Hatziliami, A | 1 |
| Fragodimitri, C | 1 |
| Karabatsos, F | 1 |
| Joussef, J | 1 |
| Mitilineou, E | 1 |
| Diamanti-Kandaraki, E | 1 |
| Meletis, J | 1 |
| Karagiorga, M | 1 |
| Tsironi, M | 2 |
| Margellis, Z | 1 |
| Deftereos, S | 2 |
| Kattamis, Ch | 1 |
| Borgna-Pignatti, C | 2 |
| Cappellini, MD | 1 |
| De Stefano, P | 1 |
| Del Vecchio, GC | 1 |
| Forni, GL | 1 |
| Gamberini, MR | 1 |
| Ghilardi, R | 1 |
| Romeo, MA | 1 |
| Zhao, H | 1 |
| Cnaan, A | 1 |
| Emara, AM | 1 |
| El Kelany, RS | 1 |
| Moustafa, KA | 1 |
| Templin, C | 1 |
| Pertschy, S | 1 |
| Schaefer, A | 1 |
| Kati, M | 1 |
| Polonifi, E | 1 |
| Marcus, RE | 1 |
| Davies, SC | 1 |
| Bantock, HM | 1 |
| Underwood, SR | 1 |
| Walton, S | 1 |
| Huehns, ER | 1 |
| Engle, MA | 2 |
| Ehlers, KH | 2 |
| O'Loughlin, JE | 1 |
| Giardina, PJ | 3 |
| Hilgartner, MW | 2 |
| Nienhuis, AW | 2 |
| Griffith, P | 2 |
| Strawczynski, H | 1 |
| Henry, W | 1 |
| Borer, J | 1 |
| Leon, M | 1 |
| Anderson, WF | 1 |
| Ley, TJ | 1 |
| Bosi, S | 1 |
| Spinolo, L | 1 |
| Cavallini, B | 1 |
| Guadagni, C | 1 |
| Lama, A | 1 |
| Santarelli, R | 1 |
| Baccini, C | 1 |
| Gabutti, V | 2 |
| Herbert, V | 1 |
| Shaw, S | 1 |
| Jayatilleke, E | 1 |
| Stopler-Kasdan, T | 1 |
| Grady, RW | 2 |
| Saad, SY | 1 |
| Najjar, TA | 1 |
| Al-Rikabi, AC | 1 |
| Caro, JJ | 1 |
| Ward, A | 1 |
| Green, TC | 1 |
| Huybrechts, K | 1 |
| Arana, A | 1 |
| Wait, S | 1 |
| Eleftheriou, A | 1 |
| Pearson, HA | 1 |
| O'Brien, RT | 1 |
| Aldouri, MA | 2 |
| Wonke, B | 2 |
| Hoffbrand, AV | 2 |
| Flynn, DM | 1 |
| Ward, SE | 2 |
| Agnew, JE | 1 |
| Hilson, AJ | 1 |
| Lerner, N | 2 |
| Blei, F | 1 |
| Bierman, F | 1 |
| Johnson, L | 1 |
| Piomelli, S | 1 |
| Freeman, AP | 1 |
| Giles, RW | 1 |
| Berdoukas, VA | 1 |
| Talley, PA | 1 |
| Murray, IP | 1 |
| Mizanin, J | 1 |
| Schwartz, E | 1 |
| Sacchetti, L | 1 |
| Sandri, A | 1 |
| Biginelli, M | 1 |
| Saracco, P | 1 |
| Ferri, M | 1 |
| Sakoda, S | 1 |
| Kinoshita, M | 1 |
| Suzuki, T | 1 |
| Itagane, H | 1 |
| Hirota, K | 1 |
| Teragaki, M | 1 |
| Akioka, K | 1 |
| Yasuda, M | 1 |
| Oku, H | 1 |
| Takeuchi, K | 1 |
| Takeda, T | 1 |
| Ochi, H | 1 |
| Maurer, HS | 1 |
| Lloyd-Still, JD | 1 |
| Ingrisano, C | 1 |
| Gonzalez-Crussi, F | 1 |
| Honig, GR | 1 |
| Farber, NE | 1 |
| Vercellotti, GM | 1 |
| Jacob, HS | 1 |
| Pieper, GM | 1 |
| Gross, GJ | 1 |
| Hyman, CB | 1 |
| Agness, CL | 1 |
| Rodriguez-Funes, R | 1 |
| Zednikova, M | 1 |
| Wolfe, L | 1 |
| Olivieri, N | 1 |
| Sallan, D | 1 |
| Colan, S | 1 |
| Rose, V | 1 |
| Propper, R | 1 |
| Freedman, MH | 1 |
| Nathan, DG | 1 |
| Link, G | 1 |
| Pinson, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Thalassemia Clinical Research Network (TCRN)[NCT00000623] | 1,000 participants (Anticipated) | Observational | 2000-07-31 | Completed | |||
| [NCT00000595] | Phase 2 | 0 participants | Interventional | 1978-01-31 | Completed | ||
| A Pilot Study of 5-Azacytidine and Oral Sodium Phenylbutyrate in Severe Thalassemia[NCT00005934] | Phase 2 | 24 participants | Interventional | 2000-06-30 | Completed | ||
| Effect of Hydroxyurea on the Level of Ineffective Erythropoiesis, Transfusion Requirement, and Fetal Hemoglobin Synthesis in Patients With Beta-Thalassemia-Intermedia[NCT00001958] | Phase 2 | 100 participants | Interventional | 1999-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for deferoxamine and Heart Diseases
| Article | Year |
|---|---|
Results of long term iron chelation treatment with deferoxamine.
Topics: Deferoxamine; Ear, Inner; Endocrine System Diseases; Eye; Heart Diseases; History, 20th Century; Hum | 2002 |
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis | 2006 |
New advances in iron chelation therapy.
Topics: Administration, Oral; Deferoxamine; Heart Diseases; Hematologic Diseases; Humans; Iron Chelating Age | 2006 |
Transfusion haemosiderosis and chelation therapy.
Topics: Adolescent; Adult; Ascorbic Acid; Blood Transfusion; Cardiomyopathies; Deferoxamine; Dose-Response R | 1982 |
Clinical manifestations and therapy of transfusional haemosiderosis.
Topics: Adolescent; Adult; Chelation Therapy; Deferoxamine; Endocrine System Diseases; Female; Heart Disease | 1994 |
Most free-radical injury is iron-related: it is promoted by iron, hemin, holoferritin and vitamin C, and inhibited by desferoxamine and apoferritin.
Topics: Animals; Anticarcinogenic Agents; Apoferritins; Ascorbic Acid; Carcinogens; Deferoxamine; Diet; Ferr | 1994 |
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Topics: Adolescent; Adult; Chelating Agents; Chelation Therapy; Child; Deferoxamine; Growth Disorders; Heari | 1995 |
1 trial available for deferoxamine and Heart Diseases
| Article | Year |
|---|---|
Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferiprone; Defero | 2011 |
43 other studies available for deferoxamine and Heart Diseases
| Article | Year |
|---|---|
Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Heart Diseases; Humans; Iron Chelating A | 2013 |
Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia.
Topics: Adult; Ceruloplasmin; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Diseases; Humans; | 2015 |
Left ventricular non-compaction in identical twins with thalassaemia and cardiac iron overload.
Topics: beta-Thalassemia; Deferoxamine; Diseases in Twins; Echocardiography; Female; Ferritins; Genetic Pred | 2009 |
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; | 2010 |
Clinicopathological and radiological study of Egyptian β-thalassemia intermedia and β-thalassemia major patients: relation to complications and response to therapy.
Topics: Absorptiometry, Photon; Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Chelation Therapy; | 2011 |
Thalassemia: cardiac iron and chelators.
Topics: Benzoates; Deferasirox; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; | 2012 |
Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-β/Smad p53 pathway in rat model.
Topics: Animals; Cardiotoxins; Deferoxamine; Disease Models, Animal; Doxorubicin; Gene Expression Regulation | 2012 |
Cardiac and pulmonary dysfunction in asymptomatic beta-thalassanemia major.
Topics: Adolescent; Asymptomatic Diseases; beta-Thalassemia; Blood Transfusion; Case-Control Studies; Child; | 2012 |
Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool.
Topics: Adult; Aged; Anemia; Case-Control Studies; Chelation Therapy; Deferoxamine; Ferritins; Follow-Up Stu | 2003 |
Surgical resection of multiple right atrial masses in a child with beta thalassaemia and receiving desferioxamine.
Topics: Adolescent; beta-Thalassemia; Calcinosis; Cardiac Catheterization; Cardiomyopathies; Catheters, Indw | 2003 |
Treatment of cardiac iron overload in thalassemia major.
Topics: beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Dise | 2003 |
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Disease-Free Survival; Female | 2003 |
Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Catheterization, Central Venous; Chelation Therapy; Deferox | 2003 |
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy.
Topics: Aged; Anemia, Refractory; Deferoxamine; Echocardiography; Fatal Outcome; Heart Diseases; Heart Ventr | 2003 |
Complications of beta-thalassemia major in North America.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; | 2004 |
Cardiac status in well-treated patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Cardiac Output; Child; Deferoxamine; Echocar | 2004 |
Impairment of cardiac function in a successful full-term pregnancy in a homozygous beta-thalassemia major: does chelation have a positive role?
Topics: Adult; beta-Thalassemia; Deferoxamine; Female; Heart Diseases; Humans; Iron Chelating Agents; Pregna | 2005 |
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Female; Ferritins; Heart Dise | 2006 |
Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Ascorbic Acid; Deferiprone; Deferoxamine; Deoxyg | 2006 |
Cardiac hemochromatosis.
Topics: Deferoxamine; Erythrocyte Transfusion; Fatal Outcome; Female; Heart Diseases; Heart Failure; Hemochr | 2007 |
Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Electrocardiography; Female; | 2007 |
Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major.
Topics: Deferoxamine; Heart Diseases; Humans; Iron; Thalassemia; Transfusion Reaction | 1984 |
Beta thalassemia and heart disease: three decades of gradual progress.
Topics: Blood Transfusion; Cardiomegaly; Child; Deferoxamine; Erythrocyte Transfusion; Heart Diseases; Human | 1985 |
Evaluation of cardiac function in patients with thalassemia major.
Topics: Adolescent; Adult; Ascorbic Acid; Child; Child, Preschool; Deferoxamine; Heart; Heart Diseases; Hear | 1980 |
[Thalassemic cardiopathy: serial echocardiographic evaluation].
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Echocardiography; Female; Ferritins; Heart | 1982 |
The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats.
Topics: Analysis of Variance; Animals; Chelating Agents; Chemical and Drug Induced Liver Injury; Deferoxamin | 2001 |
Impact of thalassemia major on patients and their families.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Cost of Illness; Deferoxamine; Diabetes Complications; E | 2002 |
The management of thalassemia major.
Topics: Adolescent; Adult; Blood Transfusion; Chelating Agents; Child; Child, Preschool; Deferoxamine; Diet | 1975 |
High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation.
Topics: Adolescent; Adult; Blood Transfusion; Chelation Therapy; Child; Combined Modality Therapy; Deferoxam | 1990 |
Chelation therapy and cardiac status in older patients with thalassemia major.
Topics: Adolescent; Adult; Chelation Therapy; Child; Deferoxamine; Drug Administration Schedule; Electrocard | 1990 |
Sustained normalization of cardiac function by chelation therapy in thalassaemia major.
Topics: Adolescent; Adult; Australia; Blood Transfusion; Chelation Therapy; Child; Combined Modality Therapy | 1989 |
Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy.
Topics: Adolescent; Adult; Anemia, Aplastic; Anemia, Sickle Cell; Catheterization, Central Venous; Deferoxam | 1989 |
Medical management of beta-thalassemia.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Erythrocyte Transfusion; Ferritins; Heart | 1989 |
Quality of life and life expectancy in thalassemic patients with complications.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Diabetes Mellitus, Type 1; Heart Diseases | 1989 |
Cardiac complications in homozygous beta-thalassemia.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Female; Heart Diseases; Homozygote; Human | 1989 |
[Left ventricular thrombi detected by Ga-67-DFO-DAS-fibrinogen imaging and two-dimensional echocardiography].
Topics: Adult; Aged; Deferoxamine; Depth Perception; Echocardiography; Female; Fibrinogen; Gallium Radioisot | 1989 |
[Detection of left ventricular thrombi after acute myocardial infarction using Ga-67-DFO-DAS-fibrinogen].
Topics: Adult; Deferoxamine; Echocardiography; Female; Fibrinogen; Gallium Radioisotopes; Heart Diseases; He | 1988 |
A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Growth; Heart Diseases; Humans; Iron; Live | 1988 |
Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in the canine heart.
Topics: Animals; Cardiomyopathies; Coronary Circulation; Deferoxamine; Dogs; Energy Metabolism; Female; Free | 1988 |
The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Deferoxamine; Echocardiography; El | 1985 |
Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia.
Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Echocardiography; Ferri | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Heart cells in culture: a model of myocardial iron overload and chelation.
Topics: Animals; Cells, Cultured; Chelating Agents; Deferoxamine; Ferritins; Heart Diseases; Hemochromatosis | 1985 |